Serina Therapeutics Files 8-K on Definitive Agreement & Asset Deal

TL;DR

Serina Therapeutics (fka AgeX) filed an 8-K for a material agreement and asset deal on 12/23.

AI Summary

Serina Therapeutics, Inc. (formerly AgeX Therapeutics, Inc.) filed an 8-K on December 26, 2024, reporting on events that occurred on December 23, 2024. The filing indicates the entry into a material definitive agreement and the completion of an acquisition or disposition of assets. Specific details regarding the agreement and the transaction are not fully elaborated in the provided text, but it falls under the 'Financial Statements and Exhibits' item.

Why It Matters

This 8-K filing signals significant corporate activity for Serina Therapeutics, potentially involving a merger, acquisition, or a major asset transaction that could impact its business and shareholder value.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement and asset transaction, which could involve significant financial and operational changes for the company, carrying inherent risks.

Key Players & Entities

• Serina Therapeutics, Inc. (company) — Registrant
• AgeX Therapeutics, Inc. (company) — Former company name
• December 23, 2024 (date) — Earliest event date
• December 26, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share SE R NYSE American Indicate
• $11.2 million — ome, Juvenescence assumed approximately $11.2 million of secured debt owed by UniverXome to J

Filing Documents

• ser-20241223.htm (8-K) — 31KB
• serinade-stockpurchaseagre.htm (EX-10.1) — 110KB
• 0001708599-24-000033.txt ( ) — 368KB
• ser-20241223.xsd (EX-101.SCH) — 2KB
• ser-20241223_lab.xml (EX-101.LAB) — 53KB
• ser-20241223_pre.xml (EX-101.PRE) — 31KB
• ser-20241223_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On December 23, 2024 , the Company entered into a Stock Purchase Agreement with JuvVentures (UK) Limited, a private limited company incorporated under the laws of England and Wales ("Juvenescence"), pursuant to which Juvenescence purchased all of the outstanding shares of UniverXome Bioengineering, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company ("UniverXome"). UniverXome was formed by AgeX in August 2023. Prior to the closing of the Merger, AgeX transferred to UniverXome substantially all assets of AgeX (the "Legacy Assets"), other than certain biological materials. In consideration of the transfer of the Legacy Assets, UniverXome had assumed (i) all indebtedness of AgeX issued to Juvenescence, and secured by the Legacy Assets, that had not been previously converted into AgeX Series A Preferred Stock or AgeX Series B Preferred Stock, and (ii) all other liabilities of AgeX in existence as of the effective time of the Merger (other than certain transaction expenses related to the Merger). The Legacy Assets included all of AgeX's interests in ReCyte Therapeutics, Inc. ("ReCyte"), Reverse Bioengineering, Inc. ("Reverse Bio") along with certain patents, patent applications, and other intellectual property, certain biological materials, certain trademarks and service marks, certain equipment, certain inventory, and certain files and records relating to the foregoing. UniverXome owns 94.8% of the outstanding capital stock of ReCyte. ReCyte owns certain pre-clinical research and development assets involving stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders and ischemic conditions. UniverXome owns 100% of the outstanding capital of Reverse Bio. Reverse Bio owns assets involved in partial cellular reprogramming using its iTR technology with the intent to revert aged or diseased cells to a healthy and functional state. As cons

01 Completion of Acquisition or Disposition of Assets

Item 2.01 Completion of Acquisition or Disposition of Assets. The disclosures set forth in Item 1.01 above are incorporated by reference into this Item 2.01.

01 - Financial Statements and Exhibits

Item 9.01 - Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Stock Purchase Agreement dated December 23, 2024, between Serina Therapeutics, Inc. and Juvenescence Limited. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERINA THERAPEUTICS, INC. Date: December 23, 2024 By: /s/ Steve Ledger Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR